Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation

Trial Profile

Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Dornase alfa (Primary)
  • Indications Respiratory tract infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
    • 11 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 04 Jan 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top